Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$8.3 million.

  • Enanta Pharmaceuticals' Cash from Financing Activities fell 1532.92% to -$8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.6 million, marking a year-over-year increase of 364.87%. This contributed to the annual value of -$26.6 million for FY2025, which is 364.87% up from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Cash from Financing Activities stood at -$8.3 million, which was down 1532.92% from -$6.4 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $199.9 million during Q2 2023, with a 5-year trough of -$8.3 million in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' median Cash from Financing Activities value was -$23000.0 (recorded in 2023), while the average stood at $8.8 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Cash from Financing Activities skyrocketed by 475133.5% in 2023, and later plummeted by 3126956.52% in 2024.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Cash from Financing Activities stood at $9.6 million in 2021, then crashed by 96.88% to $301000.0 in 2022, then tumbled by 2541.86% to -$7.4 million in 2023, then surged by 32.16% to -$5.0 million in 2024, then crashed by 66.89% to -$8.3 million in 2025.
  • Its Cash from Financing Activities stands at -$8.3 million for Q3 2025, versus -$6.4 million for Q2 2025 and -$6.9 million for Q1 2025.